Minoxidil

Other dermatologicals (topical); peripheral vasodilators (systemic)

ATC code: D11AX01 (Minoxidil (topical))

Brand names

Rogaine, Regaine, Loniten

Mechanism of action

Minoxidil is an ATP-sensitive potassium channel opener and vasodilator. The exact mechanism of hair growth stimulation is unknown. Hypothesized mechanisms include increased perifollicular blood flow, anagen phase prolongation, and follicular widening. Topical minoxidil (2% and 5%) was -approved in 1988 for androgenetic alopecia. Oral minoxidil was historically used for severe resistant hypertension; since 2017-2020 low-dose oral minoxidil (0.25-5 mg/day) has been revived in dermatology as off-label therapy for alopecia.

Indications

Androgenetic alopecia

First line

Topical minoxidil is first-line therapy for male and female androgenetic alopecia. Cochrane meta-analysis (van Zuuren 2016, 12 RCTs, n=3927) confirms significant hair count and patient satisfaction increases at 6-12 months. In men, 5% solution/foam outperforms 2%. Low-dose oral minoxidil (0.25-5 mg/day) has been studied since 2017: Vañó-Galván 2021 RCT (n=104) and multiple retrospective series show hair density gains comparable to topical, in patients intolerant or unresponsive to topical. The main side effect of oral minoxidil is facial hypertrichosis (60-90%). and BAD guidelines list topical minoxidil as first-line; low-dose oral minoxidil as second-line off-label.

Topical 5% minoxidil is approved in men aged 18+, 2% in women. Low-dose oral minoxidil is used off-label.

Sources

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

Anti-aging and longevity

Not recommended

Minoxidil is a vasodilator (originally a systemic antihypertensive). Topical forms (solution, foam) are approved for androgenic alopecia in men and women (AEMPS Ficha Técnica). Low-dose oral minoxidil (0.25-5 mg) is widely used off-label for anti-aging of hair. Clinical studies of oral minoxidil for hair loss are limited; the has not approved the drug for this indication. Oral minoxidil carries serious risks: hypertrichosis (excessive hair growth on face, back), orthostatic hypotension, tachycardia, peripheral edema, and pericardial effusion (FDA boxed warning for systemic minoxidil). If oral minoxidil was prescribed for anti-aging of hair, consider seeking a second opinion.

Sources

Practical notes

Russian practice note

In Russia, topical minoxidil is sold both as a medicinal product and as a cosmetic. A 60 mL bottle of 5% solution costs 900-1800 ₽ (one month supply). Effect appears no earlier than 12-16 weeks; optimal assessment at 6 months. Increased shedding in the first 2-8 weeks is common and not a reason to stop. After discontinuation, acquired hair is lost over 3-4 months. Low-dose oral minoxidil is not registered in Russia for alopecia and is prescribed off-label at 0.25-2.5 mg/day (men) and 0.25-1.25 mg/day (women), starting at 0.625-1.25 mg with titration.

Drug interactions

Topical minoxidil has negligible systemic absorption – clinically significant interactions are not reported. Oral minoxidil potentiates antihypertensive effects of other drugs; combination with β-blockers and diuretics reduces sodium retention and tachycardia risk. Guanethidine-containing drugs are contraindicated due to severe hypotension risk.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Official sources

Direct links to regulator labels. Open in a new tab.

AEMPS / CIMA

Spanish Medicines Information Centre (CIMA)

Label dated: 11/29/2025

FDA / DailyMed

FDA — DailyMed Drug Labels

Label dated: 02/09/2026

Safety

Contraindications

Hypersensitivity
Pregnancy and breastfeeding
Age under 18
Active scalp dermatoses (for topical form)
Severe cardiovascular disease (for oral form)
Pheochromocytoma (for oral form)

Serious adverse effects

Severe hypotension with systemic use
Pericardial effusion (classic complication of high-dose oral minoxidil; not reported at low alopecia doses)
Allergic contact dermatitis to propylene glycol vehicle

Common adverse effects

Topical: scalp irritation, itching, scaling, contact dermatitis, facial hypertrichosis (1-3%)
Telogen effluvium in the first 2-8 weeks
Oral: facial and body hypertrichosis (60-90%), lower limb edema, tachycardia, headache

PregnancyFDA C

Contraindicated in pregnancy: animal teratogenicity; oral form is FDA category C.

Breastfeeding

Contraindicated during breastfeeding: minoxidil is excreted in breast milk.

Calculate RID

Frequently asked

What is Minoxidil used for?

Minoxidil is evaluated for the following indications with varying evidence strength: Androgenetic alopecia (evidence tier A), Anti-aging and longevity (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Minoxidil?

Common side effects of Minoxidil (≥ 1 in 100): Topical: scalp irritation, itching, scaling, contact dermatitis, facial hypertrichosis (1-3%), Telogen effluvium in the first 2-8 weeks, Oral: facial and body hypertrichosis (60-90%), lower limb edema, tachycardia, headache. See the Safety section for uncommon and serious reactions.

Is Minoxidil safe during pregnancy?

FDA category C. Contraindicated in pregnancy: animal teratogenicity; oral form is FDA category C.

Is Minoxidil compatible with breastfeeding?

Contraindicated during breastfeeding: minoxidil is excreted in breast milk.

Who should not take Minoxidil?

Minoxidil is contraindicated in: Hypersensitivity; Pregnancy and breastfeeding; Age under 18; Active scalp dermatoses (for topical form); Severe cardiovascular disease (for oral form). Full list in the Safety section.